| 05/15/2026 4:01 PM | Tevogen Bio (1860871) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 04/30/2026 4:00 PM | Tevogen Bio (1860871) Filer | Form 10-K/A | |
| 04/22/2026 4:15 PM | Tevogen Bio (1860871) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 03/31/2026 4:16 PM | Tevogen Bio (1860871) Filer | Form 10-K Annual report pursuant to Section 13 or 15(d) | |
| 03/25/2026 4:04 PM | Tevogen Bio (1860871) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 03/25/2026 4:10 PM | Tevogen Bio (1860871) Filer | Form 424B3 | |
| 03/17/2026 3:29 PM | Flomenberg Neal (2011757) Reporting Tevogen Bio (1860871) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/04/2026 8:08 AM | Tevogen Bio (1860871) Filer | Form 424B3 | |
| 03/04/2026 8:04 AM | Tevogen Bio (1860871) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 02/26/2026 8:36 AM | Tevogen Bio (1860871) Filer | Form 424B3 | |
| 02/06/2026 2:09 PM | Desai Kirti (2011765) Reporting Tevogen Bio (1860871) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
This stock has 30 days of quiet left (Ad) A small power equipment company with $1.5 billion in orders is flying under the radar - but not for long. When the SpaceX and xAI S-1 filing hits the SEC in June, analysts will comb through supplier disclosures and this company's name is expected to surface.
Dylan Jovine has identified the ticker and laid out the full investment thesis. The stock is still quiet - but that window may be closing fast. See the overlooked supplier before the SpaceX S-1 changes everything |
| 01/30/2026 2:37 PM | Tevogen Bio (1860871) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 01/26/2026 4:29 PM | Tevogen Bio (1860871) Filer | Form DEF 14A | |
| 01/16/2026 4:29 PM | Tevogen Bio (1860871) Filer | Form PRE 14A | |
| 12/30/2025 9:12 AM | Desai Kirti (2011765) Reporting Tevogen Bio (1860871) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/22/2025 4:43 PM | Saadi Ryan H. (2011728) Reporting Tevogen Bio (1860871) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/16/2025 7:47 PM | Saadi Ryan H. (2011728) Filed by Tevogen Bio (1860871) Subject | Form SCHEDULE 13D/A | |
| 12/15/2025 4:31 PM | Desai Kirti (2011765) Reporting Tevogen Bio (1860871) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/12/2025 5:51 PM | Saadi Ryan H. (2011728) Reporting Tevogen Bio (1860871) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 11/14/2025 8:22 AM | Tevogen Bio (1860871) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 11/14/2025 8:25 AM | Tevogen Bio (1860871) Filer | Form 424B3 | |
| 09/26/2025 4:15 PM | Tevogen Bio (1860871) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 09/26/2025 4:18 PM | Tevogen Bio (1860871) Filer | Form 424B3 | |
| 07/25/2025 6:48 PM | Saadi Ryan H. (2011728) Filed by Tevogen Bio (1860871) Subject | Form SCHEDULE 13D/A | |
| 07/10/2025 8:18 AM | Tevogen Bio (1860871) Filer | Form 424B3 | |
| 07/10/2025 8:15 AM | Tevogen Bio (1860871) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 07/03/2025 4:23 PM | Tevogen Bio (1860871) Filer | Form 424B5 | |
| 07/03/2025 4:25 PM | Tevogen Bio (1860871) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 07/01/2025 3:48 PM | Desai Kirti (2011765) Reporting Tevogen Bio (1860871) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 07/01/2025 3:49 PM | Flomenberg Neal (2011757) Reporting Tevogen Bio (1860871) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 07/01/2025 3:49 PM | Khan Sadiq (2011764) Reporting Tevogen Bio (1860871) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 07/01/2025 3:49 PM | Saadi Ryan H. (2011728) Reporting Tevogen Bio (1860871) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/30/2025 4:21 PM | Tevogen Bio (1860871) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 06/27/2025 4:26 PM | Tevogen Bio (1860871) Filer | Form 424B3 | |
| 06/26/2025 11:15 PM | Tevogen Bio (1860871) Filer | Form EFFECT | |
| 06/23/2025 4:06 PM | Tevogen Bio (1860871) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 06/23/2025 4:09 PM | Tevogen Bio (1860871) Filer | Form 424B3 | |
| 06/20/2025 4:20 PM | Tevogen Bio (1860871) Filer | Form S-3 Registration statement under Securities Act of 1933 | |
| 06/09/2025 6:13 PM | Saadi Ryan H. (2011728) Reporting Tevogen Bio (1860871) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/09/2025 4:45 PM | Saadi Ryan H. (2011728) Reporting Tevogen Bio (1860871) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/03/2025 12:46 PM | Tevogen Bio (1860871) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
Two scenarios for the dollar - gold wins in both cases (Ad) Two scenarios are unfolding for the U.S. dollar right now - and both point toward gold. If a gold standard returns, gold would need to be repriced sharply higher to back the current money supply. If it doesn't, $39 trillion in national debt and continued dollar devaluation keep pushing gold the same direction it's already been heading.
A legal IRA rollover lets you move a portion of your 401(k) or IRA into physical gold without triggering taxes or penalties. The free 2026 Gold IRA Guide walks through how both outcomes favor gold holders and how to position your retirement savings before the window narrows. Download the free 2026 Gold IRA Guide and see your options |
| 06/03/2025 12:48 PM | Tevogen Bio (1860871) Filer | Form 424B3 | |